comparemela.com

Latest Breaking News On - Emerging infection platform trial - Page 1 : comparemela.com

BerGenBio ASA: BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS

BERGEN, Norway, Sept. 27, 2022 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical

United kingdomGraham morrellMartin olinPrnewswire bergenbioLinstitut national de la santOslo university hospitalEuropean clinical research infrastructure networkOslo stock exchangeEuropean discoveryEmerging infection platform trialChief executive officerChief investigatorSenior consultantOslo universityUniversity hospitalNorwegian securities trading

BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIE

a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe.

United kingdomMartin olinPrnewswire bergenbioLinstitut national de la santOslo university hospitalEuropean clinical research infrastructure networkOslo stock exchangeEuropean discoveryEmerging infection platform trialChief executive officerChief investigatorSenior consultantOslo universityUniversity hospitalNorwegian securities trading

BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS

/PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet.

United kingdomGraham morrellMartin olinPrnewswire bergenbioLinstitut national de la santOslo university hospitalEuropean clinical research infrastructure networkOslo stock exchangeEuropean discoveryEmerging infection platform trialChief executive officerChief investigatorSenior consultantOslo universityUniversity hospitalNorwegian securities trading

BerGenBio, Oslo University Hospital to trial bemcentinib for Covid-19

BerGenBio and Oslo University Hospital executed a collaborative agreement to analyse bemcentinib in a trial in Covid-19 patients.

Martin olinEli lillyElectronic data capture solutions for clinical trialsLinstitut national de la santEuropean medicines agencyTime data services for clinical researchOslo university hospitalEuropean clinical research infrastructure networkEuropean discoveryEmerging infection platform trialClinical trials arenaDigital magazineData capture solutionsTime data servicesClinical research

BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients

/PRNewswire/ BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs.

United kingdomChris welshMary jane elliottMartin olinEli lillyPrnewswire bergenbioLucy featherstoneEuropean union horizonLinstitut national de la santInternational media relationsEuropean medicines agencyOslo university hospitalOslo stock exchangeConsilium strategic communicationsEuropean clinical research infrastructure networkEmerging infection platform trial

vimarsana © 2020. All Rights Reserved.